RTP Mobile Logo
Visiting Professors Multiple Myeloma, Issue 1, 2014
Released July 2014

Featuring Drs Sagar Lonial and Morie A Gertz’s perspectives on their time spent visiting with patients with multiple myeloma in the clinics of community oncologists. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 10% of all hematologic cancers. It is estimated that 24,050 new cases will be diagnosed and 11,090 deaths will occur in the United States in 2014. The introduction of new agents with substantial activity has improved outcomes and allowed patients to experience longer periods of remission. Both novel proteasome inhibitors and immunomodulatory (IMiD) agents have effectively transformed the standard treatment for patients with newly diagnosed and relapsed/refractory MM. Thus, the current challenge facing the oncology community is identifying those patients who will obtain the greatest benefit from a specific regimen while incurring the least toxicity. For this reason, hematologic oncologists must be apprised of the unique risks and benefits accompanying each evidence-based treatment strategy and of the acceptable monitoring and supportive management techniques that enable early recognition of safety concerns and effective interventions to address side effects.

    To provide clinicians with therapeutic strategies to address the disparate needs of patients with MM, the Visiting Professors audio series employs an innovative case-based approach that unites the perspectives of leading hematology-oncology investigators and general oncologists as they explore the intricacies of making treatment decisions. Upon completion of this CME activity, medical oncologists should be able to formulate an up-to-date and more complete approach to the care of patients with MM.

    LEARNING OBJECTIVES

    • Apply case-based learning, innovative communication strategies and shared clinical insight to provide comprehensive and compassionate oncology care for patients with MM.
    • Integrate recent clinical research findings with proteasome inhibitors and IMiDs into the development of individualized induction and maintenance treatment strategies for patients with MM.
    • Develop an understanding of emerging efficacy and side effect data with novel agents and combination regimens under evaluation for MM.
    • Evaluate the benefits and risks of lenalidomide maintenance therapy after stem cell transplantation for patients with active MM.
    • Assess the use of bone-targeted therapy in patients with newly diagnosed MM regardless of the presence of bone disease.
    • Develop a risk-adapted treatment plan for patients with smoldering MM.
    • Assess the ongoing clinical trials evaluating therapeutic approaches for MM, and counsel appropriately selected patients for study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains an audio component. The participant should listen to the audio MP3s.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — Dr Rupard had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr LonialAdvisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Sanofi. Dr BrennerSpeakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company. Dr GertzAdvisory Committee: Onyx Pharmaceuticals Inc, Sanofi; Consulting Agreement: Celgene Corporation.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, AVEO Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Millennium: The Takeda Oncology Company and Onyx Pharmaceuticals Inc.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader (Optional)
    Sound card and speakers for audio

    Release date: July 2014
    Expiration date: July 2015

     

Acknowledge and close

Listen to audio:
Visiting Professors Multiple Myeloma, Issue 1, 2014
Released July 2014

Featuring Drs Sagar Lonial and Morie A Gertz’s perspectives on their time spent visiting with patients with multiple myeloma in the clinics of community oncologists. (Text and Audio Content)

Read print: